Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

NEXT GENERATION NANOPARTICLE-BASED ANTIBACTERIAL TREATMENT FOR INFECTED WOUNDS

Descripción del proyecto

Apósito antibacteriano para heridas crónicas infectadas

Millones de personas en todo el mundo sufren heridas crónicas que no se curan fácilmente y tienen un mayor riesgo de infección. Los tratamientos convencionales de las heridas conllevan el uso de antibióticos. Sin embargo, a menudo son ineficaces contra las bacterias farmacorresistentes, lo que provoca infecciones recurrentes e incluso amputaciones. La misión del proyecto NEXTNANO, financiado con fondos europeos, es evaluar clínicamente una innovación antibacteriana (pendiente de patente) que se basa en la nanotecnología y puede reducir en un 20 % las amputaciones relacionadas con infecciones. Esta nanotecnología original es versátil y puede utilizarse para fabricar una serie de productos antibacterianos con importantes beneficios medioambientales, sociales y económicos. El primer producto es un apósito antibacteriano para heridas diabéticas.

Objetivo

Every 5th person with diabetes develops chronic wounds that are frequently infected by bacteria. In 15−27 % cases bacterial wound infection leads to the gangrene that requires an amputation of the leg. 10 mln of amputations occur annually, showing that existing wound infection management treatments are inefficient.

NEXTNANO aims to commercialize a new antibacterial nanotechology developed by our scientists and medical doctors to reduce the number of infection-related amputations by 20%. We showed in animals studies that our first product produced on the basis of this technology, an antibacterial wound dressing, is 8x times better than the current commercial best.

Women TechEU grant would support the transition of our technology from the research and development stage to the commercialization stage. For that we have 4 Objectives: 1) To upgrade the commercialization strategy of our company; 2) To conduct the clinical assessment of our first product, antibacterial wound dressing; 3) To establish the quality management system (QMS) in our company and 4) To train participants. The main project results will be the improved commercialization strategy (including new contacts with the stakeholders), collaboration with the EU key opinion leaders and established QMS that will greatly increase the connectivity and competitiveness of our women-led deep-tech startup within innovation ecosystems of the EU. This will lead to more inclusive and gender equal innovation ecosystem in EU, since Estonia is one of the EU inclusiveness target countries and has one of the EU's highest inequalities between the salaries and top positions of women and men according to Eurostat. Not least, NEXTNANO will result in significant impacts: environmental (decreased use of antibiotics), societal (20% less amputations) and economical (10 mln eur revenue by 2026 and new high value-added jobs for 15 persons such as scientists, medical doctors, engineers and sales managers).

Ámbito científico (EuroSciVoc)

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-CSA - HORIZON Coordination and Support Actions

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) HORIZON-EIE-2021-SCALEUP-01

Ver todos los proyectos financiados en el marco de esta convocatoria

Coordinador

NANORDICA MEDICAL OU
Aportación neta de la UEn
€ 75 000,00
Dirección
MAEALUSE TN 2/1
12618 TALLINN
Estonia
Pyme
Sí
Región
Eesti Eesti Põhja-Eesti
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
Sin datos